Metachromatic leukodystrophy: an overview of current and prospective treatments
Open Access
- 1 October 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 42 (S2), S2-S6
- https://doi.org/10.1038/bmt.2008.275
Abstract
Nowadays, different treatment options are available for an extending list of lysosomal storage diseases (LSDs). Hematopoietic stem cell transplantation (HSCT) can benefit selected subsets of patients with some LSDs, but results have been poor in several other disorders, including metachromatic leukodystrophy (MLD), outlining the need for innovative therapeutic approaches in this field. Enzyme replacement therapy has been developed recently for MLD, and a Phase I/II trial is ongoing. However, the blood-brain barrier limits the access of the recombinant product to the nervous tissues. Autologous hematopoietic stem/progenitor cells can be genetically modified to constitutively express supra-physiological levels of arylsulfatase-A and may become a quantitatively more effective source of functional enzyme than normal donor cells when transplanted in patients with MLD, thus possibly overcoming the limits of HSCT. Moreover, autologous transplantation might be associated with a significantly reduced transplant-related morbidity and TRM avoiding the risk of GVHD. Therefore, such a gene therapy strategy could represent a significant advance in comparison to conventional allogeneic HSCT.Keywords
This publication has 41 references indexed in Scilit:
- Emerging trends in transplantation of inherited metabolic diseasesBone Marrow Transplantation, 2008
- Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failureBone Marrow Transplantation, 2007
- Enzyme, cell and gene‐based therapies for metachromatic leukodystrophyJournal of Inherited Metabolic Disease, 2007
- New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapyHuman Genetics, 2006
- Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in miceJCI Insight, 2006
- Trends in haematopoietic cell transplantation for inborn errors of metabolismJournal of Inherited Metabolic Disease, 2006
- Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sourcesBone Marrow Transplantation, 2003
- Practical Suggestions in Diagnosing Metachromatic Leukodystrophy in Probands andin Testing Family MembersEuropean Neurology, 1998
- Two new polymorphisms in the arylsulfatase A gene and their haplotype associations with normal, metachromatic leukodystrophy and pseudodeficiency allelesAmerican Journal of Medical Genetics, 1997
- Molecular analysis of the arylsulphatase A gene in late infantile metachromatic leucodystrophy patients and healthy subjects from Italy.Journal of Medical Genetics, 1996